Hepatocellular Carcinoma
Conditions
Interventions
Gold Standard:Diagnosed with hepatocellular carcinoma (HCC) clinically and/or pathologically per the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)
Index test:A hybrid model combining imageomics and Transformer deep learning
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Voluntarily sign an informed consent form. 2.Aged 18 years or older; 3.Received treatment at Nanfang Hospital, Southern Medical University between January 2019 and December 2025. 4.Diagnosed with hepatocellular carcinoma (HCC) clinically and/or pathologically in accordance with the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2024 Edition). 5.Underwent at least one cycle of Atezolizumab plus Bevacizumab (T+A) combination therapy. 6.Non-contrast, hepatic arterial phase, portal venous phase and delayed phase contrast-enhanced CT scans performed within 2 weeks prior to immunotherapy. 7.Minimum follow-up duration of 1 year after treatment; tumor progression was confirmed by imaging examination or pathological diagnosis in all progressive cases.
Exclusion criteria
Exclusion criteria: 1.Complicated with severe diseases of other organs. 2.Pathologically confirmed as other types of malignant hepatic tumors. 3.Spontaneous rupture and hemorrhage of tumor with intra-abdominal hematoma (true rupture). 4.Suboptimal quality of imaging data with obvious artifacts, missing areas or blank regions. 5.Absence of measurable target lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| deep features;immune molecule expression;radiomics features; | — |
Countries
China
Contacts
Public Contactlushan xiao
Southern Medical University Southern Hospital
Outcome results
None listed